₹6,580 Cr
₹467 Cr
14.09
As on 05-Jun-2023 IST
₹-10.75
•
-1.96%
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Glenmark Life Sciences
| 27.84 | 6.43 | 39.89 | 22.63 | -- | -- | -- |
|
S&P BSE Healthcare
| 4.49 | 3.84 | 10.96 | 9.18 | 14.35 | 13.31 | 10.36 |
|
S&P BSE Small Cap
| 7.32 | 5.59 | 11.48 | 17.66 | 38.98 | 13.31 | 17.96 |
|
2022
|
|
|---|---|
|
Glenmark Life Sciences
| -33.42 |
|
S&P BSE Small Cap
| -1.80 |
|
S&P BSE Healthcare
| -12.10 |
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
|
Stock
|
Peer Median
|
||
|---|---|---|---|
Please wait... |
|||
₹6,580.32 Cr
₹2,161.22 Cr
₹466.96 Cr
₹309.40 Cr
₹0.00 Cr
82.85%
High
₹370.00 - 560.10
₹2.00
12,25,27,172
BSE: 543322, NSE: GLS
Solapur, Maharashtra
www.glenmarklifesciences.com
Glenmark Life Sciences Limited develops, manufactures, and supplies non-commoditized active pharmaceutical ingredients for various chronic therapeutic areas in India. The company offers Olmesartan, Amiodarone, Telmisartan, Perindopril, Rosuvastatin,... and Cilostazol for cardiovascular diseases; Oxcarbazepine, Zonisamide, Topiramate, Bupropion, Ropinirole, Riluzole, and Lacosamide for central nervous system diseases; Glimepiride, Teneligliptin, Vildagliptin, and Linagliptin for diabetes; and Etoricoxib, Lornoxicam, Zolmitriptan, and Frovatriptan for pain management. It also provides Atovaquone, Remogliflozin, Teneligliptin, Zonisamide, and Adapalene. In addition, the company offers contract development and manufacturing services to a range of multinational pharmaceutical and specialty pharmaceutical companies. It also exports its products to Europe, North America, Latin America, Japan, and internationally. The company was incorporated in 2011 and is based in Mumbai, India. Glenmark Life Sciences Limited is a subsidiary of Glenmark Pharmaceuticals Limited. Read more
Share via Facebook 
Share via Twitter 
Share via LinkedIn 
Share this
Add Portfolio